» Articles » PMID: 25639570

Biological and Symptom Changes in Posttraumatic Stress Disorder Treatment: a Randomized Clinical Trial

Overview
Journal Depress Anxiety
Publisher Wiley
Date 2015 Feb 3
PMID 25639570
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Understanding cognitive and biological mechanisms of PTSD treatment can help refine treatments and increase rates of response.

Methods: Thirty-six veterans with PTSD were randomly assigned to receive Prolonged exposure therapy (PE) or Present-Centered therapy (PCT). We examined symptoms, trauma-related cognitions, and two indices of HPA axis function (cortisol awakening response and cortisol response to a script-driven imagery task).

Results: Thirty veterans started treatment and 26 completed. PE resulted in significantly more symptom reduction than PCT (P = .008). High treatment responders collapsed across treatments showed nominally higher cortisol levels measured at pretreatment 30 min after trauma script exposure compared to low responders (P = .08). At midtreatment, high treatment responders showed higher cortisol levels throughout the imagery task (Ps = .03-.04). There were no differences between high and low treatment responders at posttreatment. Thoughts of incompetence (F (1.6, 35.8) = 16.8, P = .000) and a dangerous world (F (1.3, 29.9) = 8.2, P = .004) significantly improved over time in high treatment responders but showed no change in low responders. Script-associated cortisol response prior to treatment and reductions in thoughts of incompetence accounted for 83% of the variance in reductions in PTSD severity with PE.

Conclusions: Both increased cortisol response to personal trauma script prior to PTSD therapy and reductions in cognitive symptoms of PTSD were significantly and uniquely related to reductions in the core symptoms of PTSD in PE. However, contrary to our hypotheses, cortisol measures were not related to cognitive changes.

Citing Articles

Latent-state and model-based learning in PTSD.

Cisler J, Dunsmoor J, Fonzo G, Nemeroff C Trends Neurosci. 2024; 47(2):150-162.

PMID: 38212163 PMC: 10923154. DOI: 10.1016/j.tins.2023.12.002.


Biological markers in clinical psychological research - A systematic framework applied to HPA axis regulation in PTSD.

Engel S, Klusmann H, Laufer S, Kapp C, Schumacher S, Knaevelsrud C Compr Psychoneuroendocrinol. 2022; 11:100148.

PMID: 35967927 PMC: 9363642. DOI: 10.1016/j.cpnec.2022.100148.


Enhancing Prolonged Exposure therapy for PTSD using physiological biomarker-driven technology.

Back S, Acierno R, Saraiya T, Harley B, Wangelin B, Jarnecke A Contemp Clin Trials Commun. 2022; 28:100940.

PMID: 35664505 PMC: 9160482. DOI: 10.1016/j.conctc.2022.100940.


Change in posttraumatic stress disorder-related thoughts during treatment: Do thoughts drive change when pills are involved?.

Rauch S, Kim H, Venners M, Porter K, Norman S, Simon N J Trauma Stress. 2022; 35(2):496-507.

PMID: 34973039 PMC: 9446312. DOI: 10.1002/jts.22762.


The temporal sequence of change in PTSD symptoms and hypothesized mediators in Cognitive Processing Therapy and Written Exposure Therapy for PTSD.

Lee D, Marx B, Thompson-Hollands J, Gallagher M, Resick P, Sloan D Behav Res Ther. 2021; 144:103918.

PMID: 34198230 PMC: 8325637. DOI: 10.1016/j.brat.2021.103918.